null Marina Klein, MD, M.Sc., FRCPC

Senior Scientist, RI-MUHC, 5252 de Maisonneuve site

Infectious Diseases and Immunity in Global Health Program

Centre for Outcomes Research and Evaluation

Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Infectious Diseases, MUHC



HIV • Hepatitis C • clinical trials • epidemiology • antiretrovirals • prospective cohort

Research Focus

My research program builds on years of multidisciplinary work leading one of the largest cohorts focused on HIV and hepatitis C virus (HCV) co-infection in the world. As Canada Research Chair in Clinical and Epidemiologic Studies of Chronic Viral Infections in Vulnerable Populations, I am documenting the impact of new HCV therapies on health outcomes, designing and testing tailored approaches to increase access to diagnosis and treatment, building capacity for research with Indigenous communities, and using evidence generated to advocate for policy change. My goal is to pave the way to eliminating HCV and other chronic viral infections in Canada and globally. To this end, I am leading an ambitious project called Montreal Sans Hep C, which aims to make Montreal the first City in North America to eliminate HCV.

Selected Publications

Click on Pubmed to see my current publications list

  • Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A, Reeves I, Habibi MS, Apea V, Boesecke C, Vandekerckhove L, Yakubovsky M, Sendagorta E, Blanco JL, Florence E, Moschese D, Maltez FM, Goorhuis A, Pourcher V, Migaud P, Noe S, Pintado C, Maggi F, Hansen AE, Hoffmann C, Lezama JI, Mussini C, Cattelan A, Makofane K, Tan D, Nozza S, Nemeth J, Klein MB, Orkin CM. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. N Engl J Med. 2022 Aug 25;387(8):679-691. doi: 10.1056/NEJMoa2207323.

  • Saeed S, Strumpf E, Moodie EEM, Wong L, Cox J, Walmsley S, Tyndall M, Cooper C, Conway B, Hull M, Martel-Laferriere V, Gill J, Wong A, Vachon ML, Klein MB; Canadian Coinfection Cohort Study Investigators. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. Clin Infect Dis. 2020 Jul 11;71(2):363-371. doi: 10.1093/cid/ciz833.

  • Sacks-Davis R, van Santen DK, Boyd A, Young J, Stewart A, Doyle JS, Rauch A, Mugglin C, Klein M, van der Valk M, Smit C, Jarrin I, Berenguer J, Lacombe K, Requena MB, Wittkop L, Leleux O, Bonnet F, Salmon D, Matthews GV, Guy R, Martin NK, Spelman T, Prins M, Stoove M, Hellard M; InCHEHC Collaboration. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies. Lancet HIV. 2024 Feb;11(2):e106-e116. doi: 10.1016/S2352-3018(23)00267-9.

  • Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, Martel-Laferriere V, Conway B, Pick N, Vachon ML, Klein MB; Canadian Co-infection Cohort Investigators. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clin Infect Dis . 2017 May 1;64(9):1154-1162. doi: 10.1093/cid/cix126.

  • Kronfli N, Young J, Wang S, Cox J, Walmsley S, Hull M, Cooper C, Martel-Laferriere V, Wong A, Pick N and Klein MB, for the Canadian Co-infection Cohort Study Investigators. Liver fibrosis in HIV-Hepatitis C virus (HCV) co-infection before and after sustained virologic response: what is the best non-invasive marker for monitoring regression? Clin Infect Dis. 2021 Aug 2;73(3):468-477. doi: 10.1093/cid/ciaa702.